Ghrelin is a prognostic marker and a potential therapeutic target in breast cancer. 2017

Malin Grönberg, and Cecilia Ahlin, and Ylva Naeser, and Eva Tiensuu Janson, and Lars Holmberg, and Marie-Louise Fjällskog
Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden.

Ghrelin and obestatin are gastrointestinal peptides, encoded by the same preproghrelin gene. Both are expressed in breast cancer tissue and ghrelin has been implicated in breast cancer tumorigenesis. Despite recent advances in breast cancer management the need for new prognostic markers and potential therapeutic targets in breast cancer remains high. We studied the prognostic impact of ghrelin and obestatin in women with node negative breast cancer. Within a cohort of women with breast cancer with tumor size ≤ 50 mm, no lymph node metastases and no initiation of adjuvant chemotherapy, 190 women were identified who died from breast cancer and randomly selected 190 women alive at the corresponding time as controls. Tumor tissues were immunostained with antibodies versus the peptides. Ghrelin expression was associated with better breast cancer specific survival in univariate analyses (OR 0.55, 95% CI 0.36-0.84) and in multivariate models, adjusted for endocrine treatment and age (OR 0.57, 95% CI 0.36-0.89). Obestatin expression was non-informative (OR 1.2, 95% CI 0.60-2.46). Ghrelin expression is independent prognostic factor for breast cancer death in node negative patients-halving the risk for dying of breast cancer. Our data implies that ghrelin could be a potential therapeutic target in breast cancer treatment.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001940 Breast In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES. Breasts
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012306 Risk The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome. Relative Risk,Relative Risks,Risk, Relative,Risks,Risks, Relative
D013548 Sweden Country in northern Europe, bordering the Baltic Sea, between Finland and Norway. The capital is Stockholm.
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers

Related Publications

Malin Grönberg, and Cecilia Ahlin, and Ylva Naeser, and Eva Tiensuu Janson, and Lars Holmberg, and Marie-Louise Fjällskog
January 2013, PloS one,
Malin Grönberg, and Cecilia Ahlin, and Ylva Naeser, and Eva Tiensuu Janson, and Lars Holmberg, and Marie-Louise Fjällskog
November 2013, Journal of cancer research and clinical oncology,
Malin Grönberg, and Cecilia Ahlin, and Ylva Naeser, and Eva Tiensuu Janson, and Lars Holmberg, and Marie-Louise Fjällskog
July 2018, Journal of cellular physiology,
Malin Grönberg, and Cecilia Ahlin, and Ylva Naeser, and Eva Tiensuu Janson, and Lars Holmberg, and Marie-Louise Fjällskog
January 2025, Frontiers in oncology,
Malin Grönberg, and Cecilia Ahlin, and Ylva Naeser, and Eva Tiensuu Janson, and Lars Holmberg, and Marie-Louise Fjällskog
January 2015, Pancreas,
Malin Grönberg, and Cecilia Ahlin, and Ylva Naeser, and Eva Tiensuu Janson, and Lars Holmberg, and Marie-Louise Fjällskog
October 2020, Aging,
Malin Grönberg, and Cecilia Ahlin, and Ylva Naeser, and Eva Tiensuu Janson, and Lars Holmberg, and Marie-Louise Fjällskog
November 2025, Cellular signalling,
Malin Grönberg, and Cecilia Ahlin, and Ylva Naeser, and Eva Tiensuu Janson, and Lars Holmberg, and Marie-Louise Fjällskog
April 2024, Pathology, research and practice,
Malin Grönberg, and Cecilia Ahlin, and Ylva Naeser, and Eva Tiensuu Janson, and Lars Holmberg, and Marie-Louise Fjällskog
August 2010, Regulatory peptides,
Malin Grönberg, and Cecilia Ahlin, and Ylva Naeser, and Eva Tiensuu Janson, and Lars Holmberg, and Marie-Louise Fjällskog
July 2015, Diagnostic pathology,
Copied contents to your clipboard!